Full Generic Medicine Info
Dosage/Direction for Use

Raynaud's syndrome
Adult: Initially, 40 mg 4 times daily, may be increased to 80 mg 4 times daily if necessary. In patients who are exposed to cold temperatures during the daytime: 40 mg 3 hourly during the period when symptoms are most likely to occur. If response is not achieved within 2 weeks, discontinue therapy.
Hepatic impairment: Active liver disease: Contraindicated.
Active liver disease.
Special Precautions
Patient with diabetes mellitus. Elderly.
Adverse Reactions
Significant: Rarely, hepatotoxicity (including hepatitis and cholestatic jaundice). Ear and labyrinth disorders: Vertigo. Gastrointestinal disorders: Diarrhoea, nausea. Nervous system disorders: Headache. Skin and subcutaneous tissue disorders: Rash. Vascular disorders: Facial flushing.
Symptom: Hypotension. Management: Put the patient in supine position until the blood pressure has been normalised.
Drug Interactions
May potentiate the effect of antihypertensive agents. Hypotensive effect may be increased by TCAs.
Moxisylyte is an α-adrenergic blocking agent that has vasodilating activity. Synonym: thymoxamine.
Absorption: Rapidly absorbed in the gastrointestinal tract.
Metabolism: Rapidly metabolised to desacetylmoxisylyte (metabolite I) and desmethyldesacetylmoxisylyte (metabolite II) which are both active metabolites.
Excretion: Via the kidneys. Elimination half-life: 1-2 hours.
Oral: Store below 30°C.
CIMS Class
Peripheral Vasodilators & Cerebral Activators
ATC Classification
C04AX10 - moxisylyte ; Belongs to the class of other peripheral vasodilators.
G04BE06 - moxisylyte ; Belongs to the class of drugs used in erectile dysfunction.
Disclaimer: This information is independently developed by CIMS based on moxisylyte from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in